ChemicalBook--->CAS DataBase List--->935888-69-0

935888-69-0

935888-69-0 Structure

935888-69-0 Structure
IdentificationBack Directory
[Name]

Oprozomib
[CAS]

935888-69-0
[Synonyms]

CS-696
PR 047
ONX-0912
OprozoMib
Axelopran
0prozomib
Oprozomib, >=98%
LY335979 ONX-0912
0prozoMib(ONX0912)
ONX-0912(Oprozomib)
OprozoMib (ONX-0912)
OPROZOMIB (ONX 0912);ONX-0912; PR-047
OPROZOMIB;ONX-0912;ONX0912;ONX 0912;PR-047;PR047;PR 047
[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid
L-Serinamide, O-methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]
Ortho-Methyl-N-[(2-Methyl-5-Thiazolyl)Carbonyl]- L-Seryl-Ortho-Methyl-N-[(1s)-2-[(2r)-2-Methyl-2- Oxiranyl]-L-Serinamide
O-Methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]-L-serinamide
L-Serinamide, O-methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]-
O-Methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]-L-serinamide Oprozomib(ONX-0912) PR 047
N-[(2S)-3-methoxy-1-[[(2S)-3-methoxy-1-[[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide
[Molecular Formula]

C25H32N4O7S
[MDL Number]

MFCD25976563
[MOL File]

935888-69-0.mol
[Molecular Weight]

532.61
Chemical PropertiesBack Directory
[Melting point ]

147-150°C (dec.)
[Boiling point ]

849.9±65.0 °C(Predicted)
[density ]

1.290±0.06 g/cm3(Predicted)
[storage temp. ]

-20°C Freezer
[solubility ]

DMSO (Slightly), Methanol (Slightly)
[form ]

Solid
[pka]

12.29±0.46(Predicted)
[color ]

White to Off-White
Hazard InformationBack Directory
[Description]

ONX 0912 is an orally bioavailable proteasome inhibitor. It potently targets the chymotrypsin-like activity of the 20S proteasome subunits β5 and LMP7 (IC50s = 36 and 82 nM, respectively). ONX 0912 inhibits the growth of multiple myeloma cells at nanomolar concentrations while not decreasing the viability of normal peripheral blood mononuclear cells at 1 μM. It blocks the growth of xenografted human multiple myeloma cells in mice when given orally. ONX 0912 has potential applications in certain types of cancer as well as other diseases that require proteasome activity.
[Uses]

Oprozomib is the second class of proteasome inhibitors with higher specificities and reduced toxicities, against head and neck squamous cell carcinoma.
[Synthesis]

(S)-2-amino-1-((R)-2-methyloxiran-2-yl)-3-phenylpropan-1-one trifluoroacetate

1148157-29-2

1010136-49-8

1010136-49-8

Oprozomib

935888-69-0

Synthesis of N-((S)-3-methoxy-1-((S)-3-methoxy-1-((S)-1-((R)-2-methoxy-2-yl)-1-oxo-3-phenylpropan-2- yl)amino)-1-oxopropan-2-yl) from compound (CAS:1148157-29-2) and compound (CAS:1010136-49-8) (Amino)-1-oxopropan-2-yl)-2-methylthiazole-5-carboxamide was prepared in the general steps as follows: in an inert atmosphere, Compound H (1.2 eq.), Compound G (1.0 eq.), H1311J (1.2 eq.), HOST (1.2 eq.), and N-methylpyrrolidinone (8 L/kg of Compound G) were added to a dry flask at 23°C and stirred until completely dissolved. Subsequently, the reaction mixture was cooled to -5 to 0 °C and diisopropylethylamine (2.1 eq.) was slowly added over 15 min while the internal reaction temperature was controlled below 0 °C. The reaction mixture continued to be stirred at 0 °C. The reaction mixture was poured into 8% sodium bicarbonate solution (40 L/kg of compound G) to precipitate crude compound 1 and the suspension was stirred at 20 to 25 °C for 12 hours. Afterwards, it was stirred at 0 to 5°C for 1 h. The white solid was obtained by filtration and washed with water (5 L/kg compound G). The white solid was then slurried in water (15 L/kg) at 20 to 25°C for 3 h. The white solid was filtered and washed with water (5 L/kg Compound G) and isopropyl acetate (2 x 2 L/kg Compound G). The white solid was dried under vacuum at 45 °C to constant weight to give crude compound 1 in 65% yield and 97.2% HPLC purity. Crude compound 1 was completely dissolved in isopropyl acetate (20 L/kg crude compound 1) by heating to 85 °C, and a clarified solution was obtained by thermal filtration to remove particulate matter before heating to 85 °C. The clarified solution was cooled to 65°C at a rate of 10°C/hour and crystalline species were added. When significant crystallization was observed, cooling was continued to 20°C at a rate of 10°C/hour and the suspension was stirred at 20°C for 6 hours, followed by stirring at 0 to 5°C for at least 2 hours. Filtration and rinsing with isopropyl acetate (1 L/kg crude compound 1) was performed and the purified compound 1 was dried under vacuum at 45 °C for at least 24 h to constant weight in a final yield of 87% and HPLC purity of 97.2%.

[Enzyme inhibitor]

This orally active inhibitor (FW = 532.61 g/mol; CAS 935888-69-0; Solubility: 105 mg/mL DMSO, <1 mg/mL H2O), also known as ONX 0912 and O-methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)-ethyl]-Lserinamide, selectively targets the chymotrypsin-like (CT-L) activity of 20S proteasome β5 (IC50 = 36 nM) and 20S proteasome LMP7 (IC50 = 82 nM). In animal tumor model studies, ONX 0912 significantly reduced tumor progression and prolonged survival. Immununostaining of multiple myeloma tumors from ONX 0912-treated mice showed growth inhibition, apoptosis, and a decrease in associated angiogenesis. Oprozomib is distinct from carfilzomib, even though the same chemistry was employed to selectively target the proteasome. Oprozomib is under development as an oral therapy for hematologic malignancies, including multiple myeloma, and for patients with recurrent or refractory solid tumors (See also Carfilzomib).
[in vivo]

Oprozomib (PR-047) selectively inhibits chymotrypsin-like (CT-L) activity of both the constitutive proteasome (β5) and immunoproteasome (LMP7) and demonstrates an absolute bioavailability of up to 39% in rodents and dogs[1].
Oprozomib promotes antitumor activity in multiple animal models by oral administration at doses below the maximum tolerated dose (MTD)[1].
Oprozomib (30 mg/kg by oral gavage once daily for 5 consecutive days followed by 2 days of rest) treatment decreases tumor burden in C57Bl/6 and NOD.SCID.IL2Rγ-/- mice[3].

Animal Model:C57Bl/6 and NOD.SCID.IL2Rγ-/- mice bearing established human RPMI-8226-luc myeloma cells[3]
Dosage:30?mg/kg
Administration:Oral gavage once daily for 5 consecutive days followed by 2 days of rest
Result:Decreased human MM tumor burden and protects mice from bone destruction.
[target]

20S proteasome β5
[References]

[1] Patent: US2014/113855, 2014, A1. Location in patent: Paragraph 0279; 0305; 0306; 0307; 0308
[2] Patent: US2018/78532, 2018, A1. Location in patent: Paragraph 0233; 0242; 0249; 0250; 0251; 0252; 0253; 0254
[3] Patent: US2010/240903, 2010, A1. Location in patent: Page/Page column 14
[4] Patent: US2018/161279, 2018, A1. Location in patent: Paragraph 0482-0483; 0492-0495; 0496-0499
Spectrum DetailBack Directory
[Spectrum Detail]

Oprozomib(935888-69-0)1HNMR
935888-69-0 suppliers list
Company Name: Shanghai Boyle Chemical Co., Ltd.  
Telephone:
Website: www.boylechem.com
Company Name: J & K SCIENTIFIC LTD.  
Telephone: 18210857532 18210857532
Website: https://www.jkchemical.com
Company Name: Chemsky(shanghai)International Co.,Ltd.  
Telephone: 021-50135380
Website: www.shchemsky.com
Company Name: Jinan Trio PharmaTech Co., Ltd.  
Telephone: 0531-88811783
Website: www.trio-pharmatech.com
Company Name: Dalian Meilun Biotech Co., Ltd.  
Telephone: 0411-62910999 13889544652
Website: http://www.meilunbio.com/
Company Name: NCE Biomedical Co.,Ltd.  
Telephone: 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
Website: www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm
Company Name: Shanghai T&W Pharmaceutical Co., Ltd.  
Telephone: +86 21 61551611
Website: www.trustwe.com
Company Name: Haoyuan Chemexpress Co., Ltd.  
Telephone: 021-58950125
Website: http://www.chemexpress.com.cn
Company Name: Nanjing Dulai Biotechnology Co., Ltd.  
Telephone: 025-84699383-8003;025-846993838003-8003 18013301590
Website: http://www.njduly.com
Company Name: EnliPharma Technology Co., Ltd  
Telephone: 0551-66399836 18955197623
Website: http://www.enlipharma.com
Company Name: Jinan Mingya Medical Technology Co., Ltd.  
Telephone: 0531-85828981
Website: www.chemicalbook.com/ShowSupplierProductsList16067/0_EN.htm
Company Name: CEG Chemical Science&Technology Co., Ltd.  
Telephone: Mobile:13665161512
Website: www.cegchemical.com
Company Name: Shanghai JONLN Reagent Co., Ltd.  
Telephone: 400-0066400 13621662912
Website: http://www.jonln.com
Company Name: Bide Pharmatech Ltd.  
Telephone: 400-164-7117 18317119277
Website: www.bidepharm.com
Company Name: AdooQ Bioscience CHINA  
Telephone: 025-58849295
Website: http://www.adooq.cn
Company Name: LETOPHARM LIMITED  
Telephone: +86-21-5821 5861
Website: www.letopharm.com
Company Name: Shanghai Lollane Biological Technology Co.,Ltd.  
Telephone: 021-52996696,15000506266 15000506266
Website: http://www.bioll.com
Company Name: Shanghaizehan biopharma technology co., Ltd.  
Telephone: 021-61350663 13052117465
Website: http://www.zehanbiopharma.com
Tags:935888-69-0 Related Product Information
179324-69-7 1201902-80-8 1072833-77-2 847499-27-8 133407-82-6 868540-17-4